Sangamo vet Gary Lee joins synthetic biology outfit Senti as CSO

Gary Lee, Ph.D.a 13-year veteran of Sangamo Therapeutics, has joined Senti Biosciences as its new chief scientific officer. In his new role, Lee will head up the expansion of Senti’s synthetic biology platform and oversee the advancement of oncology cell therapy programs into the clinic. During his tenure at Sangamo, Lee worked on T-cell engineering, including CAR-T therapies for cancer and T-cell therapies for HIV. His most recent post at Sangamo was vice president of cell therapy. His role there allowed him to have "a front-row seat” to the development of cell therapy over the years. That experience gave him deep expertise in gene editing and what it can do, but it also highlighted that some problems require different solutions. That’s what drew him to Senti.